6428 related articles for article (PubMed ID: 2720707)
1. Phase I study of recombinant human tumor necrosis factor alpha in advanced malignant disease.
Moritz T; Niederle N; Baumann J; May D; Kurschel E; Osieka R; Kempeni J; Schlick E; Schmidt CG
Cancer Immunol Immunother; 1989; 29(2):144-50. PubMed ID: 2720707
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor.
Steinmetz T; Schaadt M; Gähl R; Schenk V; Diehl V; Pfreundschuh M
J Biol Response Mod; 1988 Oct; 7(5):417-23. PubMed ID: 3183683
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of subcutaneously administered recombination tumor necrosis factor to patients with advanced malignancy.
Zamkoff KW; Newman NB; Rudolph AR; Young J; Poiesz BJ
J Biol Response Mod; 1989 Oct; 8(5):539-52. PubMed ID: 2795095
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial of recombinant human tumor necrosis factor.
Creaven PJ; Plager JE; Dupere S; Huben RP; Takita H; Mittelman A; Proefrock A
Cancer Chemother Pharmacol; 1987; 20(2):137-44. PubMed ID: 3664933
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050).
Taguchi T
Cancer Detect Prev; 1988; 12(1-6):561-72. PubMed ID: 3180146
[TBL] [Abstract][Full Text] [Related]
6. Phase I study of recombinant human tumor necrosis factor.
Kimura K; Taguchi T; Urushizaki I; Ohno R; Abe O; Furue H; Hattori T; Ichihashi H; Inoguchi K; Majima H
Cancer Chemother Pharmacol; 1987; 20(3):223-9. PubMed ID: 3315281
[TBL] [Abstract][Full Text] [Related]
7. Tumor necrosis factor alpha modifies resistance to interferon alpha in vivo: first clinical data.
Moritz T; Kloke O; Nagel-Hiemke M; Kummer G; Wandl UB; Opalka B; Plappert B; Kempeni J; Seeber S; Niederle N
Cancer Immunol Immunother; 1992; 35(5):342-6. PubMed ID: 1394338
[TBL] [Abstract][Full Text] [Related]
8. A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion.
Mittelman A; Puccio C; Gafney E; Coombe N; Singh B; Wood D; Nadler P; Ahmed T; Arlin Z
Invest New Drugs; 1992 Aug; 10(3):183-90. PubMed ID: 1428728
[TBL] [Abstract][Full Text] [Related]
9. A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma.
Kemeny N; Childs B; Larchian W; Rosado K; Kelsen D
Cancer; 1990 Aug; 66(4):659-63. PubMed ID: 2386895
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of recombinant tumor necrosis factor given in combination with recombinant interferon-gamma.
Smith JW; Urba WJ; Clark JW; Longo DL; Farrell M; Creekmore SP; Conlon KC; Jaffe H; Steis RG
J Immunother (1991); 1991 Oct; 10(5):355-62. PubMed ID: 1790143
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of recombinant interleukin-2 followed by recombinant tumor necrosis factor in patients with metastatic cancer.
Negrier MS; Pourreau CN; Palmer PA; Ranchere JY; Mercatello A; Viens P; Blaise D; Jasmin C; Misset JL; Franks CR
J Immunother (1991); 1992 Feb; 11(2):93-102. PubMed ID: 1571336
[TBL] [Abstract][Full Text] [Related]
12. Phase I trial of recombinant human tumour necrosis factor alpha in patients with advanced malignancy.
Gamm H; Lindemann A; Mertelsmann R; Herrmann F
Eur J Cancer; 1991; 27(7):856-63. PubMed ID: 1834117
[TBL] [Abstract][Full Text] [Related]
13. Local treatment of liver metastases with recombinant tumour necrosis factor (rTNF): a phase one study.
IJzermans JN; van der Schelling GP; Scheringa M; Splinter TA; Marquet RL; Jeekel J
Neth J Surg; 1991 Aug; 43(4):121-5. PubMed ID: 1944989
[TBL] [Abstract][Full Text] [Related]
14. Injection of recombinant tumor necrosis factor directly into liver metastases: an experimental and clinical approach.
IJzermans JN; Scheringa M; van der Schelling GP; Geerling RA; Marquet RL; Jeekel J
Clin Exp Metastasis; 1992 Mar; 10(2):91-7. PubMed ID: 1537138
[TBL] [Abstract][Full Text] [Related]
15. Human pharmacological investigation of a human recombinant tumor necrosis factor preparation (PAC-4D) a phase-I trial.
Lenk H; Tanneberger S; Müller U; Shiga T
Arch Geschwulstforsch; 1988; 58(2):89-97. PubMed ID: 3377652
[TBL] [Abstract][Full Text] [Related]
16. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
17. Phase I clinical and pharmacological study of merbarone.
Dimaggio JJ; Warrell RP; Muindi J; Stevens YW; Lee SJ; Lowenthal DA; Haines I; Walsh TD; Baltzer L; Yaldaei S
Cancer Res; 1990 Feb; 50(4):1151-5. PubMed ID: 2297763
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of recombinant tumor necrosis factor (rTNF) administered by continuous intravenous infusion in patients with disseminated malignancy.
Schwartz JE; Scuderi P; Wiggins C; Rudolph A; Hersh EM
Biotherapy; 1989; 1(3):207-14. PubMed ID: 2642024
[TBL] [Abstract][Full Text] [Related]
19. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
Hallahan DE; Vokes EE; Rubin SJ; O'Brien S; Samuels B; Vijaykumar S; Kufe DW; Phillips R; Weichselbaum RR
Cancer J Sci Am; 1995; 1(3):204-9. PubMed ID: 9166477
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study.
Whitehead RP; Fleming T; Macdonald JS; Goodman PJ; Neefe J; Braun TJ; Swinnen LJ; Hersh EM
J Biol Response Mod; 1990 Dec; 9(6):588-91. PubMed ID: 2074444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
